A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
- Sponsor
- National Taiwan University Hospital
- Study ID
- NCT04147351
- Phase
- PHASE2
- Status
- Completed
Conditions
- NSCLC Stage IIIB~IV
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Atezolizumab Injection; bevacizumab Injection — DRUGa PD-L1 inhibitor; anti-angiogenesis
Study Details
using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
Key Dates
- Start date
- Apr 10, 2020
- Status verified
- Apr 2026
- Primary completion
- Feb 4, 2026
- Completion
- Feb 4, 2026
Study Design
- Enrollment
- 22 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin
Primary Outcome Measure
Objective response rate (ORR) [ Time Frame: 9 MONTHS ]